N-Acetyltransferase 10 Enhances Doxorubicin Resistance in Human Hepatocellular Carcinoma Cell Lines by Promoting the Epithelial-to-Mesenchymal Transition

Table 1

IC₅₀ values and statistical analyses of doxorubicin (DOX) and remodelin (Remo) treatments in HCC cell lines.

	IC50^a
	Dox	Remo	Dox+Remo	Combination index
Huh7	1.687 (0.9574-2.416)	465.3 (-1676-2607)	Dox 0.8271 (0.6688-0.9854); Remo 8.271 (6.688-9.854)	0.5080
BEL-7402	0.7633 (0.5844-0.9422)	29.33 (-1.089-59.76)	Dox 0.4677 (0.3895-0.5459); Remo 4.677 (3.895-5.459)	0.7721
SNU-387	9.178 (-6.944 to 25.30)	1752 (-4078-7583)	Dox 1.313 (0.8707-1.756); Remo 13.13 (8.707-17.56)	0.1505
SNU-449	23969 (-249863-297802)	1036 (-4182-6255)	Dox 2.379 (1.219-3.539); Remo 23.79 (12.19-35.39)	0.0230

^aIC₅₀ values show doxorubicin (μg/mL) and remodelin concentration (μM) (concentration, mean (95% confidence intervals)).